Cohance Lifesciences Q3 Results
- BSE: 543064
- NSE: COHANCE
- ISIN: INE03QK01018
- Sector: Biotechnology & Drugs
BSE
454.50
-31.25 (-6.43%)
-31.25 (-6.43%)Volume3.94 L
Updated: Wed 13 May, 2026 | 15:06:27
NSE
454.15-30.50 (-6.29%)
-30.50 (-6.29%)Volume4.52 M
Updated: Wed 13 May, 2026 | 14:51:42
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹544.55 Cr.(77.29%)
- Operating Profit₹43.55 Cr.(-55.26%)
- Profit After Tax₹36.72 Cr.(-55.69%)
- Operating Margin8.00%(-74.77%)
Note: Comparison is on YoY basis
Quarterly - Cohance Lifesciences Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 501.00 | 436.19 | 4.67% | 167.43 | 138.80% |
| Depreciation/ Amortization | 46.94 | 37.79 | 6.63% | 12.75 | 130.66% |
| Operating Income | 43.55 | 167.58 | -43.39% | 52.39 | -55.26% |
| Net Income | 36.72 | 138.47 | -50.43% | 46.75 | -55.69% |
| Other Operating Expenses Total | 171.61 | 122.86 | 2.90% | 14.42 | 143.31% |
| Net Income Before Taxes | 40.60 | 174.16 | -51.53% | 65.47 | -63.00% |
| Total Revenue | 544.55 | 603.77 | -1.98% | 219.82 | 77.29% |
| Selling/ General/ Admin Expenses Total | 118.68 | 102.07 | -6.34% | 32.83 | 87.52% |
| Diluted Normalized EPS | 1.05 | 3.61 | -45.55% | 1.84 | -67.47% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.